B&K Corporation Limited
2396.HK
Hong Kong Stock Exchange4.55
HKD
-0.05
- -
ISIN
CNE100007CT6
Return %
Stock
S&P500
1Y
-83.15
22.23
3Y
-83.15
69.34
5Y
-83.15
73.59
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jun Hui Zhai
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 1 Qingdao SD People's Republic of China
- IPO Date
- Dec 21, 2025
- Website
- huarenshengwu.com
- Similar Companies
- Business
- B&K Corporation Limited, a biopharmaceutical company focused on protein-based wound healing therapies, operates primarily in China with a growing footprint in international markets. The company discovers, develops, and commercializes PDGF-based products for indications with high medical need and significant market opportunities, aiming to address burn care and related wound healing applications. Headquarters are located in Qingdao, China, and the firm was founded in 2012, transitioning to its current name in 2024. Main Products and Services - PDGF-based wound healing therapies: rhPDGF-bB–driven products targeting wound care, including core candidates Pro-101-1 for burns and Pro-101-2 for diabetic or chronic wounds; development and commercialization extend to other PDGF drug candidates within the pipeline. - Biopharmaceutical R&D services: early discovery through preclinical development activities for protein-based therapeutics, with emphasis on translational research, formulation development, and preclinical safety studies. - Clinical development and regulatory support: planning and execution of clinical programs in relevant geographies, including regulatory strategy, interactions with authorities, and documentation for trials and approvals. - Manufacturing and supply chain readiness: process development, scale-up capabilities, GMP-compliant manufacturing transfers, and supply chain planning to support clinical and commercial demands. Latest Major Company Changes - Corporate rebranding and corporate structure: changes to the corporate name in 2024 to B&K Corporation Limited, reflecting a strategic repositioning within the biopharmaceutical sector. - Strategic focus on protein-based wound therapies: continued emphasis on PDGF drug candidates, with updates to the development pipeline and potential expansion into additional wound care indications. - Partnerships and collaborations: ongoing alliances to accelerate development and commercialization in China and select international markets, including potential co-development and licensing discussions with partners in biomedical and pharmaceutical sectors. - Financial and corporate developments: efforts to secure funding and strategic investments to support clinical programs, manufacturing scale-up, and expansion into key markets. - Operational enhancements: expansion of manufacturing capabilities and quality systems to support clinical trial material production and eventual commercial supply, along with organizational realignment to support rapid development timelines. Additional Context - Industry and segments: biopharmaceuticals, with a specialization in protein therapeutics for wound healing; pipeline centers on PDGF-based modalities. - Target markets: primarily China for development and potential commercialization, with exploratory activities and partnerships aimed at international markets. - Geographic operations: headquartered in Qingdao, China, with activities spanning domestic development, regulatory engagement, and potential international collaborations; manufacturing-related activities may involve facilities in China to support clinical and early-commercial needs. - Founding year and headquarters: founded in 2012; headquarters in Qingdao, China. - Subsidiaries/parent relationships: corporate structure includes entities under the B&K umbrella following the 2024 rebranding; strategic arrangements with collaborators and potential licensing partners shape operational scope. Note: Information reflects public disclosures and periodically updated corporate data as of the latest reporting windows. For the most current and precise details, consult the company’s official disclosures and filings.